Article | March 31, 2020

Virtual Panel: Leveraging A Biomanufacturing Legacy To Support New Business

Grifols

The biomanufacturing legacy of the Grifols campus in Emeryville, California, began with Chiron and Cetus in the 1980s, with innovative advancements in yeast expression, viral discovery and the development of PCR. Three decades of process development and manufacturing experience is the foundation of the business today at Grifols Recombinant Protein Contract Development and Manufacturing Organization (CDMO).

Recently, Grifols expanded its focus to apply its expertise to producing therapeutic proteins for biopharmaceutical organizations. Its new GMP consolidated manufacturing facility (CMF) supports this expansion. The CMF facility houses multiproduct production and features state-of-the-art equipment, including a distributed control system and a central data historian. We sat down with seven diverse experts at Grifols Recombinant Protein CDMO to discuss how the group’s legacy and recent investments support its future in providing recombinant protein CDMO services.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to:

CHIRONĀ® Recombinant Proteins